Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
about
Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneityClinical application of genetics to guide prevention and treatment of oral diseasesIdentifying potential indicators to measure the outcome of translational cancer research: a mixed methods approachGetting personalized cancer genome analysis into the clinic: the challenges in bioinformaticsIdentification of a long non-coding RNA NR_026689 associated with lung carcinogenesis induced by NNKImaging biomarker roadmap for cancer studiesPrecision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development.Genome-wide analysis of gynecologic cancer: The Cancer Genome Atlas in ovarian and endometrial cancer.Next-generation sequencing in clinical oncology: next steps towards clinical validationIntegrated next-generation sequencing and avatar mouse models for personalized cancer treatment.High expression of MAGE-A9 in tumor and stromal cells of non-small cell lung cancer was correlated with patient poor survivalPersonal genomes, quantitative dynamic omics and personalized medicineDevelopment and validation of a scalable next-generation sequencing system for assessing relevant somatic variants in solid tumors.Overexpression of MAGE-A9 Is Predictive of Poor Prognosis in Epithelial Ovarian Cancer.Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean InstitutionCancer/testis antigens and urological malignanciesOxygen-Enhanced MRI Accurately Identifies, Quantifies, and Maps Tumor Hypoxia in Preclinical Cancer ModelsPrognostic Value of KIF2A and HER2-Neu Overexpression in Patients With Epithelial Ovarian Cancer.Next-generation companion diagnostics: promises, challenges, and solutions.From drug discovery to biomarker-driven clinical trials in lymphomaTherapeutic application of monoclonal antibodies in cancer: advances and challenges.Implementing personalized cancer genomics in clinical trials.Cancer proteomics: developments in technology, clinical use and commercialization.Applying nanomedicine in maladaptive inflammation and angiogenesis.Pharmacogenomic biomarkers as inclusion criteria in clinical trials of oncology-targeted drugs: a mapping of ClinicalTrials.gov.Patient and Other Stakeholder Engagement in Patient-Centered Outcomes Research Institute Funded Studies of Patients with Kidney DiseasesA rational free energy-based approach to understanding and targeting disease-causing missense mutationsChallenges in the codevelopment of companion diagnostics.'Toxgnostics': an unmet need in cancer medicine
P2860
Q26992272-C7C756B1-9B04-47CC-A58B-9674908630EBQ26999507-05CBBD7B-E0D4-4888-B713-8043A344C140Q27303882-0D729844-D647-4C01-9E8D-855C8FEECBA5Q28394818-B163F999-F128-4919-AF70-2437CA9ADF66Q28828601-BE2B2FF1-0B02-45A8-A9BA-FCB27517E788Q30242020-2266D41F-8574-4213-A7BE-D9079DE4728EQ31017820-4EB2699A-6F5C-4235-8EB6-9F95ED2FF416Q33598001-722853E9-B8DF-4B75-A1D4-A432033C40B8Q34774908-11C3980A-096A-424A-86F7-BF0CD5E320D0Q35067532-3944BBB2-A9B5-40A8-A06E-874B265020E6Q35144956-4F8BF11E-AA29-4BA5-978A-90E47F2597F3Q35195408-0699C818-A46F-4516-BAA3-3E2D1358639EQ35555483-BF0AC180-3B57-4FB5-9149-18C966F9254BQ35852265-FE6C84DD-62CD-4D3A-A6B9-38E47377FEF5Q35997083-13833A59-14D4-421A-B0F7-9A1AE65589FCQ36337004-14529E38-5DE2-43C4-AA1B-BBFC3066A516Q36591139-BC11575F-3894-470B-9CBC-A2867AC01840Q36653584-210033CF-1517-4AAB-BB55-1EFA83CB53BBQ37190679-9D95AA47-E3FD-4F3A-ABA4-D011FBDBB1B5Q37551148-F056F063-E7E8-42B3-9982-3A269D9DD161Q38057179-B276020B-0444-4BD9-83E3-14F3A0130786Q38102920-1F54E1A1-21C7-413E-939B-873DBFBB1752Q38543009-F1538EF7-D85B-4502-8372-2296B5F19024Q38557650-AE13B3D0-3232-47F9-9D0A-14919E89B504Q40197692-F0BB0626-BF56-4521-B1A3-68EB7B865B3BQ41022564-92867E16-541E-488A-BDFF-298AE2122166Q42250997-12E8D900-7BDE-4BA3-907D-16A0F69FA3F8Q53870892-96655F44-BF87-4453-9B4E-EDF77DE3C91AQ56675475-F930239A-F7EC-4B3C-8A60-AFA753EFD9EB
P2860
Making personalized cancer medicine a reality: challenges and opportunities in the development of biomarkers and companion diagnostics.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Making personalized cancer med ...... ers and companion diagnostics.
@en
Making personalized cancer med ...... ers and companion diagnostics.
@nl
type
label
Making personalized cancer med ...... ers and companion diagnostics.
@en
Making personalized cancer med ...... ers and companion diagnostics.
@nl
prefLabel
Making personalized cancer med ...... ers and companion diagnostics.
@en
Making personalized cancer med ...... ers and companion diagnostics.
@nl
P2093
P1476
Making personalized cancer med ...... ers and companion diagnostics.
@en
P2093
Bruce E Johnson
David R Parkinson
George W Sledge
P304
P356
10.1158/1078-0432.CCR-11-2017
P407
P577
2012-02-01T00:00:00Z